Personal information

No personal information available

Biography

Research scientist with experience in biochemistry and biomedical sciences. Specialized in cancer research and the use of functional studies to identify new potential drug targets, drug combination strategies and biomarkers of drug response.

Activities

Employment (1)

The Francis Crick Institute: London, GB

2016-06-01 to present
Employment
Source: Self-asserted source
Miriam Molina Arcas

Works (45)

Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy

Clinical Cancer Research
2023-12-15 | Journal article
Contributors: Jesse Boumelha; Miriam Molina-Arcas; Julian Downward
Source: check_circle
Crossref

Antibodies against endogenous retroviruses promote lung cancer immunotherapy.

Nature
2023-04-12 | Journal article | Author
Contributors: Ng KW; Boumelha J; Katey Enfield; Jorge Almagro; Cha H; Oriol Pich; Takahiro Karasaki; Moore DA; Roberto Salgado; Sivakumar M et al.
Source: Self-asserted source
Miriam Molina Arcas

Characterisation of a cyclic peptide that binds to the RAS binding domain of phosphoinositide 3-kinase p110α.

Scientific reports
2023-02-02 | Journal article
Contributors: Ismail M; Martin SR; George R; Francesca M Houghton; Kelly G; Chaleil RAG; Anastasiou P; Xinyue Wang; O'Reilly N; Federico S et al.
Source: Self-asserted source
Miriam Molina Arcas

An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations.

Cancer research
2022-10-01 | Journal article | Author
Contributors: Jesse Boumelha; Sophie de Carne Trecesson; Emily Law; Pablo Romero-Clavijo; Coelho MA; Kevin W Ng; Mugarza E; christopher moore; Rana S; Deborah R Caswell et al.
Source: Self-asserted source
Miriam Molina Arcas

Therapeutic KRAS<sup>G12C</sup> inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.

Science advances
2022-07-20 | Journal article
Contributors: Miriam Molina Arcas
Source: Self-asserted source
Miriam Molina Arcas

The Potency of a <i>KRAS</i> Silent Variant.

The New England journal of medicine
2022-06-01 | Journal article
Contributors: Miriam Molina Arcas
Source: Self-asserted source
Miriam Molina Arcas

Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry.

Nature communications
2021-10-08 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer.

Science translational medicine
2021-07-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Inherited duplications of PPP2R3B predispose to nevi and melanoma via a C21orf91-driven proliferative phenotype.

Genetics in medicine : official journal of the American College of Medical Genetics
2021-06-18 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Drugging the Undruggable: Advances on RAS Targeting in Cancer.

Genes
2021-06-10 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections.

BMC medicine
2021-04-27 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy.

Epilepsy & behavior : E&B
2020-11-05 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Scalable and robust SARS-CoV-2 testing in an academic center.

Nature biotechnology
2020-08-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers.

Lancet (London, England)
2020-07-09 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

IGF1-mediated human embryonic stem cell self-renewal recapitulates the embryonic niche.

Nature communications
2020-02-07 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.

Science translational medicine
2019-09-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas
grade
Preferred source (of 2)‎

RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.

Cancer cell
2019-06-27 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.

Nature communications
2019-06-10 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.

Immunity
2017-12-12 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression.

Nature communications
2016-04-13 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Hypoxia and P1 receptor activation regulate the high-affinity concentrative adenosine transporter CNT2 in differentiated neuronal PC12 cells.

The Biochemical journal
2013-09-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.

Cancer discovery
2013-03-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Aquaporin 3 (AQP3) participates in the cytotoxic response to nucleoside-derived drugs.

BMC cancer
2012-09-27 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.

Cell research
2012-05-22 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.

Cell
2012-04-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

How to fool a wonder drug: truncate and dimerize.

Cancer cell
2012-01-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Role of nucleoside transporters in nucleoside-derived drug sensitivity.

Nucleosides, nucleotides & nucleic acids
2010-06-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

The human concentrative nucleoside transporter-3 C602R variant shows impaired sorting to lipid rafts and altered specificity for nucleoside-derived drugs.

Molecular pharmacology
2010-04-26 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Nucleoside transporter proteins.

Current vascular pharmacology
2009-10-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3.

The Journal of pharmacology and experimental therapeutics
2009-01-13 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.

Haematologica
2008-10-22 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

A splice variant of the SLC28A3 gene encodes a novel human concentrative nucleoside transporter-3 (hCNT3) protein localized in the endoplasmic reticulum.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2008-09-30 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Physiological and pharmacological roles of nucleoside transporter proteins.

Nucleosides, nucleotides & nucleic acids
2008-06-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells.

The Journal of pharmacology and experimental therapeutics
2007-11-27 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells.

Biochemical pharmacology
2007-10-13 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5'-DFUR in breast cancer MCF7 cells.

Biochemical pharmacology
2006-09-11 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma.

Haematologica
2006-07-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

3'-Azido-2',3'-dideoxythymidine (zidovudine) uptake mechanisms in T lymphocytes.

Antiviral therapy
2006-01-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Cell entry and export of nucleoside analogues.

Virus research
2005-02-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells.

Leukemia
2005-01-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1).

Antiviral therapy
2004-12-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Nucleoside transporters in chronic lymphocytic leukaemia.

Leukemia
2004-03-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.

Clinical cancer research : an official journal of the American Association for Cancer Research
2003-10-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia.

Blood
2002-10-31 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Complex regulation of nucleoside transporter expression in epithelial and immune system cells.

Molecular membrane biology
2001-01-01 | Journal article
Source: Self-asserted source
Miriam Molina Arcas

Peer review (5 reviews for 4 publications/grants)

Review activity for Advanced science. (2)
Review activity for Communications biology. (1)
Review activity for Molecular diagnosis & therapy. (1)
Review activity for Nature cancer. (1)